Acting Commissioner Ostroff Brings Infectious Disease Background

Hamburg will leave FDA in hands of career government official who is relative pharma unknown, but could be a strong advocate for new antibiotic pathways being pushed by Congress.

The pharmaceutical industry has under two months to get to know its new regulator-in-chief before he takes over. Questions about Commissioner Margaret Hamburg’s soon-to-be acting replacement, Stephen Ostroff, currently FDA’s chief scientist, leave insiders speechless – with many knowing little to nothing of the man who may lead FDA until a new president takes over in 2017.

Hamburg announced Feb. 5 that Hamburg will step down at the end of March, and while many had speculated that...

More from United States

More from North America